Full Breakdown
Record Uptake of GLP-1 Weight-Loss Drugs Signals Shift in U.S. Obesity Landscape
7/10/2026, 11:41:09 AM
Core Findings: Surge in GLP-1 Use and Declining Obesity Rate
A Gallup poll of 5,065 U.S. adults conducted May 28 – June 5 2026 shows that 11 percent of Americans are currently taking a GLP-1 medication for weight loss, up from 3 percent in 2024. An additional 15 percent have used a GLP-1 at some point, a nine-point increase over the prior year. Concurrently, the adult obesity rate fell to 36.4 percent in 2026, down from the record-high 39.9 percent in 2022.
Background & Context
The FDA approved Novo Nordisk’s semaglutide-based drug Wegovy for obesity in 2021 and Eli Lilly’s tirzepatide-based Zepbound in late 2023. An oral formulation of Wegovy received approval in late 2025, expanding delivery options beyond subcutaneous injection.
Data & Statistics
- Brand-name GLP-1s (e.g., Ozempic, Wegovy, Zepbound) account for 68 percent of current users.
- Compounded or custom-mixed versions are used by 19 percent, with one-third of those having switched from a brand name, often citing insurance coverage gaps.
- Effectiveness: roughly three-quarters of all users rate their medication “effective” or “extremely effective”; 40 percent of compounded-drug users report “extremely effective” versus 32 percent of brand-name users.
- Cost: private-insurance coverage remains inconsistent; out-of-pocket prices can approach $500 per month. A Trump-administration temporary “Bridge” program launched July 1 2026 offers Medicare beneficiaries the drug for $50 per month.
Official Statements & Responses
- Dr. Mehmet Oz, Administrator of the Centers for Medicare & Medicaid Services, said the Bridge program “makes these medications more affordable and accessible” and noted that “for too long, many Americans have been unable to access these treatments because of cost.”
- The Trump administration announced the $50-per-month Medicare coverage as a “landmark win for access and for the future of the fight against obesity in America.”
Criticism & Opposition
Health experts highlight persistent affordability issues for commercially insured patients and warn that compounded products lack FDA approval, raising safety concerns. Additionally, GLP-1 efficacy appears reduced in adults 65 years and older, and side effects such as severe nausea, altered taste, and rare gastrointestinal complications have been reported.
Conflicting Reports & Gaps
All sources agree on the 11 percent current-use figure and the 36.4 percent obesity rate; no contradictory statistics appear. However, long-term safety data for newer oral formulations and compounded versions remain limited, representing a notable evidence gap.
Verbatim Quotes
- “For too long, many Americans have been unable to access these treatments because of cost,” — Dr. Mehmet Oz, CMS Administrator
- “The Medicare GLP-1 Bridge changes that by making these medications more affordable and accessible,” — Dr. Mehmet Oz, CMS Administrator
- “While brand-name GLP-1s continue to significantly lead the marketplace, the lower cost of compounded or custom-mixed varieties is fueling a shift away from brand-name choices and is likely making GLP-1s available to broader sectors of the population.” — Dan Witters, Gallup Research Director
- “On the public side, the Trump administration this month launched a temporary program to cover GLP-1 drugs for some Medicare patients for just$50 a month.” — Trump administration
What’s Next
The oral Wegovy pill, approved in late 2025, is expected to broaden adoption further. Ongoing Medicare negotiations may lower prices for additional beneficiaries, while researchers continue to monitor effectiveness in older adults and assess the safety profile of compounded GLP-1 products.
